Catalent.com
Contact Us
  • Biologics
    • Integrated Solutions
    • Drug Substance
    • Drug Product
    • Analytical Services
  • Gene Therapy
    • Integrated Solutions
    • Plasmid DNA
    • Process Development
    • CGMP Manufacturing
    • Analytical Services
  • Cell Therapy
    • Integrated Solutions
    • iPSCs
    • Process Development
    • CGMP Manufacturing
    • Analytical Services
    • Cell Type Solutions
  • Specialty
    • Bioconjugates
    • Bispecifics
    • Plasmid DNA
    • mRNA
    • Vaccines
    • Oncolytic Viruses
    • Orphan Drugs
  • Technologies
    • Cell Line Development (GPEX®)
    • Antibody Drug Conjugates (SMARTag®)
    • AAV Vectors
  • Expert Content
    • Biologics Analytical Services
    • Biologics Development
    • Drug Substance Manufacturing
    • Drug Product Manufacturing
    • Cell Therapy
    • Gene Therapy
    • Subscribe
  • About Us
    • Overview
    • News & Events
    • Our Leadership
    • Locations
    • Site Tours
  • Careers
Contact Us
Main menu
  • Biologics
    • Integrated Solutions
    • Drug Substance
    • Drug Product
    • Analytical Services
  • Gene Therapy
    • Integrated Solutions
    • Plasmid DNA
    • Process Development
    • CGMP Manufacturing
    • Analytical Services
  • Cell Therapy
    • Integrated Solutions
    • iPSCs
    • Process Development
    • CGMP Manufacturing
    • Analytical Services
    • Cell Type Solutions
  • Specialty
    • Bioconjugates
    • Bispecifics
    • Plasmid DNA
    • mRNA
    • Vaccines
    • Oncolytic Viruses
    • Orphan Drugs
  • Technologies
    • Cell Line Development (GPEX®)
    • Antibody Drug Conjugates (SMARTag®)
    • AAV Vectors
  • Expert Content
    • Biologics Analytical Services
    • Biologics Development
    • Drug Substance Manufacturing
    • Drug Product Manufacturing
    • Cell Therapy
    • Gene Therapy
    • Subscribe
  • About Us
    • Overview
    • News & Events
    • Our Leadership
    • Locations
    • Site Tours
  • Careers
  • Catalent.com

CATALENT ACQUIRES US COMMERCIAL CELL THERAPY FACILITY

Establishing US-based campus to support late-stage and commercial manufacturing for autologous and allogeneic cell therapies

Learn More

CATALENT INVESTS $350 MILLION AT BLOOMINGTON, INDIANA SITE

Expanding Biomanufacturing and Fill/Finish Capabilities

Learn More

CATALENT ACQUIRES FACILITY IN OXFORDSHIRE TO EXPAND BIOLOGICS CAPABILITIES IN THE UK AND ACROSS EUROPE

Expanding Biomanufacturing and Fill/Finish Capabilities

Learn More

DEVELOPING BIOLOGICS DRUGS IS SCIENCE

Accelerating Advanced Treatments & Vaccines is Art.

Learn More

How can we work together

BIOLOGICS
GENE THERAPY
CELL THERAPY
TECHNOLOGIES

Latest News

Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic

UPTEMPO VIRTUOSO™ AAV PLATFORM PROCESS
A scalable, CGMP-ready process providing early-stage partners with accelerated timelines for production of their clinical material.
LEARN MORE
PLASMID DNA
Catalent offers plasmid DNA supply and solutions from early-stage lead identification to GMP manufacturing for clinical- and commercial-scale.
Gene Therapy
Our Gene Therapy team combines leading expertise in viral vector technology and scale-up with state-of-the-art CGMP facilities, including dedicated plasmid DNA manufacturing sites and our FDA approved commercial facility.
STRATEGIES TO ACHIEVE SUCCESSFUL COMMERCIAL APPROVAL & LAUNCH
Experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the successful launch and approval of a biologic.
BIOLOGICS NETWORK
Our network of biologics sites provides an integrated approach to get medicines to your patients faster anywhere in the world.
LEARN MORE
JOIN OUR TEAM
Catalent is growing in Biologics and is making significant investments in people in this area. Explore global career opportunities with our Biologics team.

NEWS

  • Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
  • Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech
  • Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility
  • Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe
VIEW ALL NEWS

EVENTS

  • ON Helix 2022 – Leveraging Proven Technology to Speed Path to First-In-Human Studies with GPEx® Lightning
  • CASSS Bioassays 2022
VIEW ALL EVENTS

EXPERT CONTENT

Advances in Analytical Technology for Biopharmaceuticals

Prefilled Syringes & Parenteral Manufacturing

Accelerating Method Transfer: Effective Automation Of Biological Assays

VIEW ALL ARTICLES
Expert Content Subscribe Investors Contact Us Site Map
Follow Us. Share Us.
By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our Privacy Policy | Privacy Shield Statement | Cookies Settings.
Copyright 2022, Catalent, Inc - All Rights Reserved
Terms Modern Slavery Statement
Copyright 2020, Catalent, Inc - All Rights Reserved
SIGN UP NOW TO STAY CURRENT WITH THE LATEST NEWS AND INSIGHTS
SUBSCRIBE NOW
SIGN UP NOW TO STAY CURRENT
WITH THE LATEST NEWS AND INSIGHTS
SUBSCRIBE NOW